Hepatic flares promote rapid decline of serum hepatitis B surface antigen (HBsAg) in patients with HBsAg seroclearance: A long-term follow-up study. (Q51279529)

From Wikidata

Jump to navigation Jump to search

scientific article published on 7 May 2015

Language	Label	Description	Also known as
English	Hepatic flares promote rapid decline of serum hepatitis B surface antigen (HBsAg) in patients with HBsAg seroclearance: A long-term follow-up study.	scientific article published on 7 May 2015

Statements

scholarly article

1 reference

Europe PubMed Central

2 April 2018

http://europepmc.org/abstract/MED/25951079

Hepatic flares promote rapid decline of serum hepatitis B surface antigen (HBsAg) in patients with HBsAg seroclearance: A long-term follow-up study. (English)

1 reference

Europe PubMed Central

2 April 2018

http://europepmc.org/abstract/MED/25951079

author name string

Shinya Nagaoka

1

1 reference

Europe PubMed Central

2 April 2018

http://europepmc.org/abstract/MED/25951079

Seigo Abiru

2

1 reference

Europe PubMed Central

2 April 2018

http://europepmc.org/abstract/MED/25951079

Atsumasa Komori

3

1 reference

Europe PubMed Central

2 April 2018

http://europepmc.org/abstract/MED/25951079

Ryu Sasaki

4

1 reference

Europe PubMed Central

2 April 2018

http://europepmc.org/abstract/MED/25951079

Shigemune Bekki

5

1 reference

Europe PubMed Central

2 April 2018

http://europepmc.org/abstract/MED/25951079

Satoru Hashimoto

6

1 reference

Europe PubMed Central

2 April 2018

http://europepmc.org/abstract/MED/25951079

Akira Saeki

7

1 reference

Europe PubMed Central

2 April 2018

http://europepmc.org/abstract/MED/25951079

Kazumi Yamasaki

8

1 reference

Europe PubMed Central

2 April 2018

http://europepmc.org/abstract/MED/25951079

Kiyoshi Migita

9

1 reference

Europe PubMed Central

2 April 2018

http://europepmc.org/abstract/MED/25951079

Minoru Nakamura

10

1 reference

Europe PubMed Central

2 April 2018

http://europepmc.org/abstract/MED/25951079

Hironori Ezaki

11

1 reference

Europe PubMed Central

2 April 2018

http://europepmc.org/abstract/MED/25951079

Hiroshi Yatsuhashi

12

1 reference

Europe PubMed Central

2 April 2018

http://europepmc.org/abstract/MED/25951079

publication date

7 May 2015

1 reference

Europe PubMed Central

2 April 2018

http://europepmc.org/abstract/MED/25951079

Hepatology Research

1 reference

Europe PubMed Central

2 April 2018

http://europepmc.org/abstract/MED/25951079

46

1 reference

Europe PubMed Central

2 April 2018

http://europepmc.org/abstract/MED/25951079

E89-99

1 reference

Europe PubMed Central

2 April 2018

http://europepmc.org/abstract/MED/25951079

3

1 reference

Europe PubMed Central

2 April 2018

http://europepmc.org/abstract/MED/25951079

Chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12533

21 January 2018

Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance.

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12533

21 January 2018

Long-term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12533

21 January 2018

Sero-clearance of hepatitis B surface antigen in chronic carriers does not necessarily imply a good prognosis

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12533

21 January 2018

HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12533

21 January 2018

Development of hepatocellular carcinoma after seroclearance of hepatitis B surface antigen

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12533

21 January 2018

Spontaneous loss of hepatitis B surface antigen in chronic carriers, based on a long-term follow-up study in Goto Islands, Japan.

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12533

21 January 2018

Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study.

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12533

21 January 2018

Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12533

21 January 2018

A large case-control study on the predictability of hepatitis B surface antigen levels three years before hepatitis B surface antigen seroclearance.

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12533

21 January 2018

Decreasing levels of HBsAg predict HBsAg seroclearance in patients with inactive chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12533

21 January 2018

Frequent coinfection with hepatitis B virus strains of distinct genotypes detected by hybridization with type-specific probes immobilized on a solid-phase support.

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12533

21 January 2018

Hepatitis flares and hepatitis B e antigen seroconversion: implication in anti-hepatitis B virus therapy

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12533

21 January 2018

Hepatitis B flares in chronic hepatitis B: pathogenesis, natural course, and management

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12533

21 January 2018

Quantification of serum hepatitis B surface antigen: is it useful for the management of chronic hepatitis B?

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12533

21 January 2018

Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters.

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12533

21 January 2018

HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12533

21 January 2018

Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12533

21 January 2018

A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12533

21 January 2018

Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during Peg-interferon {alpha}-2b therapy

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12533

21 January 2018

Close monitoring of hepatitis B surface antigen levels helps classify flares during peginterferon therapy and predicts treatment response

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12533

21 January 2018

IFN-α inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12533

21 January 2018

Serum hepatitis B surface antigen kinetics in severe reactivation of hepatitis B e antigen negative chronic hepatitis B patients receiving nucleoside/nucleotide analogues

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12533

21 January 2018

Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: on-treatment kinetics of HBsAg serum levels vary by HBV genotype

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12533

21 January 2018

GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12533

21 January 2018

Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12533

21 January 2018

Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12533

21 January 2018

Identifiers

10.1111/HEPR.12533

1 reference

Europe PubMed Central

2 April 2018

http://europepmc.org/abstract/MED/25951079

1 reference

Europe PubMed Central

2 April 2018

http://europepmc.org/abstract/MED/25951079

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51279529&oldid=1267087322"